MedTrace Logo

Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA

NCT02322723 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-02-19

No results posted yet for this study

Summary

In Israel, data is lacking regarding the long-term effectiveness of Adalimumab in outpatient real life setting. Moreover, the association between long-term effectiveness of Adalimumab and patients' functional status as well as cultural aspects of sick leaves and visits to physician's clinics has not been demonstrated in this population. This study will collect the required data in real life settings.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Dina Meyuhas, PhD · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2020-02-29
Completion
2020-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322723 on ClinicalTrials.gov